title: Intranasal immunization of young mice with a multigene HIV-1 vaccine in combination with the N3 adjuvant induces mucosal and systemic immune responses.
abstract: One of the major challenges for the development of an HIV vaccine is to induce potent virus-specific immune responses at the mucosal surfaces where transmission of virus occurs. Intranasal delivery of classical vaccines has been shown to induce good mucosal antibody responses, but so far for genetic vaccines the success has been limited. This study shows that young individuals are sensitive to nasal immunization with a genetic vaccine delivered in a formulation of a lipid adjuvant, the Eurocine N3. Intranasal delivery of a multiclade/multigene HIV-1 genetic vaccine gave rise to vaginal and rectal IgA responses as well as systemic humoral and cellular responses. As electroporation might become the preferred means of delivering genetic vaccines for systemic HIV immunity, nasal delivery by droplet formulation in a lipid adjuvant might become a means of priming or boosting the mucosal immunity.
authors.affiliation: Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet and Swedish Institute for Infectious Disease Control, Stockholm, Sweden. andreas.brave@smi.ki.se
authors.forename: Andreas
authors.initials: A
authors.lastname: Bråve
authors.forename: David
authors.initials: D
authors.lastname: Hallengärd
authors.forename: Ulf
authors.initials: U
authors.lastname: Schröder
authors.forename: Pontus
authors.initials: P
authors.lastname: Blomberg
authors.forename: Britta
authors.initials: B
authors.lastname: Wahren
authors.forename: Jorma
authors.initials: J
authors.lastname: Hinkula
mesh_terms: D016915:AIDS Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D000276:Adjuvants, Immunologic; D000281:Administration, Intranasal; D000818:Animals; D005243:Feces / Q000737:chemistry; D005260:Female; D015483:HIV Antibodies / Q000032:analysis / Q000096:biosynthesis; D015658:HIV Infections / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D015497:HIV-1 / Q000235:genetics / Q000276:immunology; D054298:Human Immunodeficiency Virus Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D018928:Immunity, Mucosal; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000097:blood; D008055:Lipids / Q000008:administration & dosage / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D010957:Plasmids / Q000235:genetics; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D013601:T-Lymphocytes / Q000276:immunology; D014611:Vaccination; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology; D014621:Vagina / Q000276:immunology
chemical_list: D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D015483:HIV Antibodies; D054298:Human Immunodeficiency Virus Proteins; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D008055:Lipids; D011993:Recombinant Fusion Proteins; D019444:Vaccines, DNA